| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell Analysis Systems, Inc., Elmhurst, Illinois 60126 [S. S. B., C. R. Z., D. C., R. S.]; University of Illinois, Chicago, Illinois 60612 [A. V. G.]; Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel [I. S., E. P., N. B-B., M. S., Y. Y.]; Israel Cancer Research Fund, Givat Shmuel 51905, Israel [H. F.]; The Vincent T. Lombardi Cancer Center, Georgetown University, Washington, DC 20007 [R. L.]; and Amgen Center, Thousand Oaks, California 91320 [D. W.]
Neu differentiation factor (NDF, also called heregulin) is a 44-kilodalton glycoprotein that stimulates tyrosine phosphorylation of the Neu/HER-2 receptor and induces phenotypic differentiation of certain mammary cancer cell lines to growth-arrested and milk-producing cells. To determine which molecules participate in the concomitant morphological alterations, we analyzed the expression of several cytoskeletal and surface molecules and found that NDF elevated the expression of the intercellular adhesion molecule 1 (ICAM-1) in cultured AU-565 human adenocarcinoma cells. The levels of both the protein and the mRNA of ICAM-1 were elevated after 3–5 days of treatment with NDF. Elevated expression of ICAM-1 was induced also by 
-interferon and by the tumor-promoting phorbol ester (PMA), albeit with different kinetics. Down-regulation of protein kinase C or its inhibition by calphostin C partially inhibited the effect of NDF, implying that the induction of ICAM-1 may be mediated by protein kinase C.
NDF transcripts were detectable in 3 of 9 human mammary tumors, suggesting that the in vitro effect of the factor may be relevant to breast cancer. By selecting Neu-positive human mammary tumors (n = 39), we found a significant correlation (P < 0.001) between the expression of ICAM-1 and histological features of invasive ductal carcinoma with a prominent carcinoma in situ component. When cultured in vitro the cells of these tumors grew in clusters and formed domelike structures reminiscent of comedo-type carcinoma in situ. In addition, the majority of patients with tumors that coexpressed ICAM-1 and Neu had no lymph node involvement, unlike most Neu-positive but ICAM-1-negative tumors, which metastasized to the lymphatic system. Taken together, our observations suggest that the induction of ICAM-1 by NDF may affect the morphology, differentiation state, and metastasis of Neu-expressing mammary tumor cells.
1 Supported by NIH Grants CA50843 (to S. S. B.) and CA51712 (to Y. Y.) and the Minna-James Heinemann Foundation.
2 To whom requests for reprints should be addressed, at Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.
Received 5/ 4/93. Accepted 8/25/93.
This article has been cited by other articles:
|
|
 |
|
  S.-M. Feng, C. I. Sartor, D. Hunter, H. Zhou, X. Yang, L. S. Caskey, R. Dy, R. S. Muraoka-Cook, and H. S. Earp III The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell Proliferation Mol. Endocrinol., August 1, 2007; 21(8): 1861 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Kochupurakkal, D. Harari, A. Di-Segni, G. Maik-Rachline, L. Lyass, G. Gur, G. Kerber, A. Citri, S. Lavi, R. Eilam, et al. Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity J. Biol. Chem., March 4, 2005; 280(9): 8503 - 8512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, S. S. Bacus, M. Sela, and Y. Yarden Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy PNAS, February 8, 2005; 102(6): 1915 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang and A. W. Hamburger Heregulin Regulates the Ability of the ErbB3-binding Protein Ebp1 to Bind E2F Promoter Elements and Repress E2F-mediated Transcription J. Biol. Chem., June 18, 2004; 279(25): 26126 - 26133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xia, A. Cheng, D. Akinmade, and A. W. Hamburger The N-Terminal 24 Amino Acids of the p55 Gamma Regulatory Subunit of Phosphoinositide 3-Kinase Binds Rb and Induces Cell Cycle Arrest Mol. Cell. Biol., March 1, 2003; 23(5): 1717 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Atlas, M. Cardillo, I. Mehmi, H. Zahedkargaran, C. Tang, and R. Lupu Heregulin Is Sufficient for the Promotion of Tumorigenicity and Metastasis of Breast Cancer Cells in Vivo Mol. Cancer Res., January 1, 2003; 1(3): 165 - 175. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z. Suo, B. Risberg, M. G. Karlsson, K. Villman, E. Skovlund, and J. M. Nesland The Expression of EGFR Family Ligands in Breast Carcinomas International Journal of Surgical Pathology, April 1, 2002; 10(2): 91 - 99. [Abstract] [PDF]
|
|
|
|
 |
|
 H. You, W. Yu, B. G. Sanders, and K. Kline RRR-{alpha}-Tocopheryl Succinate Induces MDA-MB-435 and MCF-7 Human Breast Cancer Cells to Undergo Differentiation Cell Growth Differ., September 1, 2001; 12(9): 471 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Sartor, H. Zhou, E. Kozlowska, K. Guttridge, E. Kawata, L. Caskey, J. Harrelson, N. Hynes, S. Ethier, B. Calvo, et al. HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells Mol. Cell. Biol., July 1, 2001; 21(13): 4265 - 4275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. R. Gilmour, K. G. Macleod, A. McCaig, W. J. Gullick, J. F. Smyth, and S. P. Langdon Expression of erbB-4/HER-4 Growth Factor Receptor Isoforms in Ovarian Cancer Cancer Res., March 1, 2001; 61(5): 2169 - 2176. [Abstract] [Full Text]
|
|
|
|
|
|
S. Xiong, R. Grijalva, L. Zhang, N. T. Nguyen, P. W. Pisters, R. E. Pollock, and D. Yu Up-Regulation of Vascular Endothelial Growth Factor in Breast Cancer Cells by the Heregulin-{beta}1-activated p38 Signaling Pathway Enhances Endothelial Cell Migration Cancer Res., February 1, 2001; 61(4): 1727 - 1732. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. S.R. Spencer, D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases J. Cell Biol., January 24, 2000; 148(2): 385 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Tang, X.-Z. W. Concepcion, M. Milan, X. Gong, E. Montgomery, and M. E. Lippman Ribozyme-mediated Down-Regulation of ErbB-4 in Estrogen Receptor-positive Breast Cancer Cells Inhibits Proliferation Both in Vitro and in Vivo Cancer Res., October 1, 1999; 59(20): 5315 - 5322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tan, R. Grijalva, and D. Yu Heregulin {beta}1-activated Phosphatidylinositol 3-Kinase Enhances Aggregation of MCF-7 Breast Cancer Cells Independent of Extracellular Signal-regulated Kinase Cancer Res., April 1, 1999; 59(7): 1620 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ronen, R. T. Altstock, M. Firon, L. Mittelman, T. Sobe, J. H. Resau, G. F. Vande Woude, and I. Tsarfaty Met-HGF/SF Mediates Growth Arrest and Differentiation in T47D Breast Cancer Cells Cell Growth Differ., February 1, 1999; 10(2): 131 - 140. [Abstract] [Full Text]
|
|
|
|
|
|
C. Niemann, V. Brinkmann, E. Spitzer, G. Hartmann, M. Sachs, H. Naundorf, and W. Birchmeier Reconstitution of Mammary Gland Development In Vitro: Requirement of c-met and c-erbB2 Signaling for Branching and Alveolar Morphogenesis J. Cell Biol., October 19, 1998; 143(2): 533 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Crovello, C. Lai, L. C. Cantley, and K. L. Carraway III Differential Signaling by the Epidermal Growth Factor-like Growth Factors Neuregulin-1 and Neuregulin-2 J. Biol. Chem., October 9, 1998; 273(41): 26954 - 26961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pinkas-Kramarski, M. Shelly, B. C. Guarino, L. M. Wang, L. Lyass, I. Alroy, M. Alamandi, A. Kuo, J. D. Moyer, S. Lavi, et al. ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network Mol. Cell. Biol., October 1, 1998; 18(10): 6090 - 6101. [Abstract] [Full Text]
|
|
|
|
|
|
L.-M. Wang, A. Kuo, M. Alimandi, M. C. Veri, C.-C. Lee, V. Kapoor, N. Ellmore, X.-H. Chen, and J. H. Pierce ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4 PNAS, June 9, 1998; 95(12): 6809 - 6814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Waterman, I. Sabanai, B. Geiger, and Y. Yarden Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency J. Biol. Chem., May 29, 1998; 273(22): 13819 - 13827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shelly, R. Pinkas-Kramarski, B. C. Guarino, H. Waterman, L.-M. Wang, L. Lyass, M. Alimandi, A. Kuo, S. S. Bacus, J. H. Pierce, et al. Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes J. Biol. Chem., April 24, 1998; 273(17): 10496 - 10505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Carver, P. M. Mathew, and W. E. Russell Hepatic Expression of ErbB3 Is Repressed by Insulin in a Pathway Sensitive to PI-3 Kinase Inhibitors Endocrinology, December 1, 1997; 138(12): 5195 - 5201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Anton, M. Marchionni, K. Lee, and P Rakic Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex Development, January 9, 1997; 124(18): 3501 - 3510. [Abstract] [PDF]
|
|
|
|
|
|
R. S. Carver, M. X. Sliwkowski, S. Sitaric, and W. E. Russell Insulin Regulates Heregulin Binding and ErbB3 Expression in Rat Hepatocytes J. Biol. Chem., June 7, 1996; 271(23): 13491 - 13496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, G. Levkowitz, E. Tzahar, D. Karunagaran, S. Lavi, N. Ben-Baruch, O. Leitner, B. J. Ratzkin, S. S. Bacus, and Y. Yarden An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 J. Biol. Chem., March 29, 1996; 271(13): 7620 - 7629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Culouscou, G. W. Carlton, and A. Aruffo HER4 Receptor Activation and Phosphorylation of Shc Proteins by Recombinant Heregulin-Fc Fusion Proteins J. Biol. Chem., May 26, 1995; 270(21): 12857 - 12863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Siegall, S. S. Bacus, G. D. Plowman, B. Mixan, D. Chace, D. M. Chin, A. Goetze, J. M. Green, I. Hellström, and H. P. Fell HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein J. Biol. Chem., March 31, 1995; 270(13): 7625 - 7630. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
